RESEARCH ANALYTICS / DOSE CONTEXT
GHK-Cu dosage as it appears in the research record
The concentrations, routes, and stability conditions reported in the literature — logged as study parameters, never as a usage protocol.
Concentrations reported in research
GHK-Cu dosage in the literature spans a wide range because the routes and models differ. In vitro, the fibroblast collagen response is the best-characterized dose-response: stimulation began between 10^-12 and 10^-11 M and peaked near 10^-9 M [1]. Topical cosmetic and clinical formulations run roughly 0.05% to 2% (w/w) in creams, serums, and gels. The human hair-loss RCT used a 5-ALA+GHK combination at 50 to 100 mg/mL applied to the scalp [4].
Rodent systemic studies used their own ranges by model and route — intraperitoneal dosing in pulmonary and silicosis models, intranasal dosing in aging and cognition models, and oral gavage in colitis models. These are logged as the parameters of specific animal experiments. None of these figures is a human dose. The readout's framing throughout is 'studied at X in this species/model by this route' — never a recommendation, because no human dosing protocol for systemic GHK-Cu has a peer-reviewed basis.
Systemic research models and their doses
Beyond topical use, GHK and GHK-Cu have been dosed systemically in rodents across several disease models, and the readout logs these as the parameters of specific experiments — never as human protocols. Pulmonary models used intraperitoneal GHK at 0.2, 2, and 20 ug/g/day on alternate days in emphysema and at 2.6, 26, and 260 ug/mL/day in fibrosis; silicosis models used 2 and 20 mg/kg intraperitoneally. A DSS-colitis model used 20 mg/kg oral gavage daily, and aging and Alzheimer cognition models used intranasal GHK at 15 mg/kg daily or three times weekly. Rat behavioral studies spanned roughly 0.5 ug/kg to 0.5 mg/kg intraperitoneally.
The span is enormous — from sub-microgram to milligram-per-kilogram — because the models, routes, and endpoints differ, and because some studies dose the free peptide while others dose the chelate. That heterogeneity is exactly why a single composite dose chart would mislead: there is no shared axis across a topical cosmetic percentage, an intranasal cognition dose, and an in vitro molar concentration. Each figure is meaningful only inside its own model. None translates to a human systemic dose, and none has a validated human pharmacokinetic basis.
Routes studied and the delivery problem
The routes in the literature are diverse: topical (cream, serum, liposome, nano-lipid carrier, ionic-liquid microemulsion, wound dressing, hydrogel, nanofiber), intraperitoneal and intravenous/subcutaneous in rodent studies, intranasal in cognitive studies, oral gavage in colitis models, and intradermal/microneedle delivery in hair studies. The dominant human route by far is topical.
Topical delivery is governed by one obstacle. Free GHK is highly hydrophilic, clogP -2.24, so it crosses the intact stratum corneum poorly [15]. The research responses are palmitoylation (Pal-GHK, clogP 1.14), liposomal encapsulation, ionic-liquid microemulsions, and microneedle pretreatment, which permeated about 134 nmol GHK against essentially none through intact skin [15]. Where copper does penetrate as GHK-Cu, it forms a bounded dermal depot — about 97 ug/cm^2 retained over 48 hours, a permeability coefficient of 2.43 x 10^-4 cm/h [5]. The depot gives prolonged local availability without unbounded uptake.
Half-life and stability
No rigorous human pharmacokinetic half-life has been published for GHK-Cu. The free tripeptide (340.38 Da) is rapidly cleared by plasma peptidases; a rat HPLC study documented rapid metabolism of GHK to the dipeptide HK after IV dosing, and secondary literature cites a short systemic elimination half-life on the order of 1 to 2 hours, with the copper chelate more stable than free GHK [from research dosage record]. The honest readout is that no validated human systemic half-life exists.
Stability is the practical counterpart to dosing. The GHK-Cu complex is most stable near pH 5 to 6.5 at a 1:1 copper-to-peptide ratio; the blue-violet color of a reconstituted solution is the expected Cu(II) absorption of an intact complex, while a brown or green shift indicates oxidation or precipitation [15]. Strong reducing agents — ascorbic acid below about pH 3.5 — reduce Cu(II) and break the complex; AHAs, BHAs, and low-pH actives can also destabilize it or compete for copper [15]. The stability constant of log K ~16.4 is what keeps the complex intact under benign conditions [7].
What the dose-response data actually means
The most informative dose figure in the GHK-Cu literature is not a milligram amount but a concentration window. Collagen synthesis in human fibroblasts responded across 10^-12 to 10^-9 M, a picomolar-to-nanomolar range, with the effect independent of cell number [1]. That low effective concentration is mechanistically important: GHK-Cu behaves like a signaling molecule operating at physiological trace levels, not a bulk substrate consumed in proportion to dose. The angiogenic alginate-hydrogel work similarly reported dose-dependent VEGF secretion across 1 to 500 ng/mL with no cytotoxicity at the top of that range [11].
This matters for how the literature should be read. A higher applied concentration in a topical study is largely a strategy to push enough intact peptide past the penetration barrier so that picomolar-to-nanomolar tissue levels are reached at the target cells — not evidence that more is intrinsically better at the receptor. Because the active window is narrow and low, the binding chemistry, stability, and delivery route do more to determine the delivered tissue concentration than the nominal applied amount, which is why this readout treats route and formulation as first-class dose variables.